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ABC of palliative care
Principles of control of cancer pain
Marie Fallon, Geoffrey Hanks, Nathan Cherny
Pain is a complex phenomenon that is the subjective end point
of a variety of physical and non-physical factors. For most
patients, physical pain is only one of several symptoms of
cancer. Relief of pain should therefore be seen as part of a
comprehensive pattern of care encompassing the physical,
psychological, social, and spiritual aspects of suffering. Physical
aspects of pain cannot be treated in isolation from other
aspects, nor can patients’ anxieties be effectively addressed
when patients are suffering physically. The various components
must be addressed simultaneously.
Our understanding of the basic mechanisms of pain has
improved considerably over the past few years. We now know
that physical injury, pain pathways, and our emotional
processing of this information are interlinked in the nervous
system. Anxiety, fear, and sleeplessness feed into the limbic
system and cortex. In turn, the brain talks back to the spinal
cord modifying pain input at spinal levels. This then feeds back
to the brain and a loop is established.
Mood disturbance is common in patients with uncontrolled
cancer pain and may need specific management. Sometimes,
however, mood will improve when the pain is resolved. Hence
the first principle of managing cancer pain is a full assessment
of the causes of all pain. With effective assessment and a
systematic approach to the choice of analgesics using the World
Health Organization’s three step analgesic ladder, over 80% of
cancer pain can be controlled with inexpensive drugs that can
be self administered by mouth.
WHO analgesic ladder
The analgesic ladder remains the mainstay of our approach to
analgesia, although it was not designed for use in isolation.
Surgery, radiotherapy, and appropriate tumoricidal treatments
have an important role in some patients, as will non-drug
treatments. A combined approach can lead to optimum
analgesia with minimum side effects.
Analgesic drugs, however, remain key in managing cancer
pain. The choice of drug should be based on the severity of the
pain, not the stage of disease. Drugs should be given in standard
doses at regular intervals in a stepwise fashion. If a non-opioid
or, in turn, an opioid for moderate pain is not sufficient, an
opioid for severe pain should be used.
When a non-opioid drug is used with an opioid for
moderate pain, many patients find combination formulations
more convenient. Care must be taken with the dose of each
drug in the formulation; some combinations of codeine or
dihydrocodeine with aspirin or paracetamol (including
co-codamol and co-dydramol) contain subtherapeutic doses of
the opioid. The decision to use an opioid for severe pain should
be based on severity of pain and not on prognosis.
Adjuvant analgesics
Adjuvant analgesic drugs may be usefully added at any stage.
An adjuvant analgesic is a drug whose primary indication is for
something other than pain but that has an analgesic effect in
some painful conditions.
This article is adapted from the second edition of the
ABC of Palliative Care, which will be published by
Blackwells in the autumn and available from
www.hammicksbma.com and all good medical
bookshops
Physical pain
• Other symptoms
• Adverse effects of treatment
Anxiety
• Fear of hospital or nursing home
• Fear of pain
• Worry about family and finances
• Fear of death
• Spiritual unrest, uncertainty about future
Depression
• Loss of social position
• Loss of job prestige
   and income
• Loss of role in family
• Insomnia and chronic
   fatigue
• Sense of helplessness
• Disfigurement
Anger
• Bureaucratic bungling
• Delays in diagnosis
• Unavailable physicians
• Uncommunicative
   physicians
• Failure of therapy
• Friends who do not
   visit
Integrated pain and
mood pathways
Total pain
Factors affecting patient’s perceptions of pain (adapted from Twycross RG,
Lack SA, Therapeutics in terminal disease, London: Pitman, 1984)
Non-drug treatments for cancer pain
TENS (transcutaneous electrical nerve stimulation)
Physiotherapy
Acupuncture
Relaxation therapy
Opioid for moderate to severe pain
 ± Non-opioid
 ± Adjuvant
Freedom from cancer pain
Ste
p 3
Opioid for mild to moderate pain
 ± Non-opioid
 ± Adjuvant
Pain persisting or increasing
Ste
p 2
± Non-opioid
 ± Adjuvant
Pain persisting or increasing
Pain
Ste
p 1
WHO analgesic ladder (adapted from WHO’s Cancer pain relief and palliative
care. Technical report series 804)
Practice
1022 BMJ VOLUME 332 29 APRIL 2006 bmj.com
Tricyclic antidepressants and anticonvulsants
Tricyclic antidepressants are sometimes helpful in relieving
neuropathic pain. Efficacy is similar for all the tricyclic
antidepressants, although side effects often limit their use. The
evidence for venlafaxine is less strong, but it can be useful,
particularly in patients with both neuropathic pain and low
mood. High level evidence is lacking for use of selective
serotonin reuptake inhibitors in neuropathic pain.
The anticonvulsants carbamazepine, phenytoin, sodium
valproate, clonazepam, gabapentin, and pregabalin are
sometimes partially effective in treating neuropathic pain.
Benefit is independent of the characteristics of the pain.
Gabapentin and pregabalin are licensed for neuropathic pain.
There is no measurable difference in the analgesic benefit of
tricyclic antidepressants and anticonvulsants in neuropathic
pain or in the number of patients needed to treat before a
minor or major adverse effect occurs. Gabapentin seems to
cause fewer side effects in many patients, although this has not
been systematically examined in patients with cancer pain.
Antidepressants and anticonvulsants may occasionally be
prescribed simultaneously, although it is good practice to
introduce one drug at a time.
Opioid analgesics for severe pain
Morphine is the most commonly used opioid for severe pain.
When possible, it should be given by mouth, with the tailored
dose repeated at regular intervals so that the pain does not
return. There is no arbitrary upper limit.
Dose titration—A normal release formulation of morphine
(either elixir or tablet), with a rapid onset and short duration of
action, is preferred for dose titration. The simplest method is to
prescribe a regular four hourly dose but allow extra doses of the
same size for “breakthrough pain” as often as necessary. After
24 or 48 hours, the daily requirements can be reassessed and
the regular dose adjusted as necessary. This process is
continued until pain relief is satisfactory. This method can take
into account the many factors that contribute to the variability
in dose, including severity of pain, type of pain, the affective
component of pain, and variation in pharmacokinetic
properties. The regular four hourly dose may range from 5-10
mg to ≥ 250 mg (or the equivalent in controlled release tablets).
Most patients require < 200 mg a day.
Maintenance dose—Patients with advancing disease and
increasing pain may require continual adjustment of dose.
Many patients, however, experience a period of stability during
which the dose required remains unchanged or needs only
small adjustments, and this may last for weeks, months, or
sometimes longer. Once the dose is established, maintenance
should be with a controlled release preparation. Controlled
release morphine is available as a once daily or twice daily
preparation, lasting 24 or 12 hours.
Alternative routes of administration
The rectal bioavailability of morphine is similar to its oral
bioavailability. The rectal route may be appropriate for patients
unable to take drugs by mouth, and the same dose as that taken
orally should be given every four hours.
For many patients unable to take drugs orally, however, it
may be more convenient to convert to a subcutaneous infusion
of opioid via an infusion device such as a portable, pocket sized,
syringe driver. The relative potency of opioids is increased when
they are given parenterally: the oral dose of morphine should
be halved to get the equianalgesic dose of subcutaneous
morphine and the oral dose of morphine halved or divided by
Criteria for choosing drugs for neuropathic pain
x Relative contraindications
x Possible drug interactions
x Risks of side effects
Common adjuvant analgesics for cancer pain
Drugs Indications
Non-steroidal
anti-inflammatories
Bone pain
Soft tissue infiltration
Hepatomegaly
Corticosteroids Raised intracranial pressure
Soft tissue infiltration
Nerve compression
Hepatomegaly
Antidepressants
Anticonvulsants
Antiarrhythmics
Nerve compression or infiltration
Paraneoplastic neuropathies
Bisphosphonates Bone pain
The skilled use of morphine will confer benefit rather
than harm, but many patients express fears, which
should be discussed
Opioid alternatives to morphine
x Hydromorphone—Titration is usually with hydromorphone normal
release capsules; when pain is controlled, patients may convert to
controlled release preparation. As it is about seven times stronger
than morphine, care is needed in patients with no previous
exposure to opioids
x Oxycodone—Can be up to 1.5 times stronger than morphine. Similar
titration to morphine and hydromorphone
x Methadone—Specialist advice should be sought
x Fentanyl—Self adhesive patches provide transcutaneous delivery of
strong opioid. The patch is changed once every 72 hours. It is used
with normal release morphine for breakthrough pain. It is suitable
only for patients whose pain is stable because of the time required
to titrate the dose upwards. It takes up to 24-48 hours before peak
plasma concentrations are achieved
x Buprenorphine—Transdermal, as above, and may have advantages in
patients with renal dysfunction
x Diamorphine, available only in the United Kingdom and Canada, is
a semisynthetic derivative and a prodrug of morphine. Use of oral
diamorphine is an inefficient way of delivering morphine to the
body, but, for parenteral administration, its greater solubility confers
an advantage over morphine
x Pethidine is a short acting opioid and not appropriate for the
management of chronic pain
Portable syringe driver for automatic drug infusion
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three, depending on the clinical situation when switching to
parenteral diamorphine. Patients rarely require intravenous
administration of morphine. It can, however, be appropriate for
those with an indwelling central line, particularly children.
Which opioid for cancer pain?
Comparative trials of opioids in cancer pain are very difficult to
perform and do not always answer our questions because of the
complexity of the populations studied. Questions also exist
about the appropriateness of randomised controlled trials in
patients with advanced cancer.
No strong evidence supports the superiority of one opioid
over another. However, the balance between analgesia and side
effects varies among opioids because of factors such as
pharmacokinetic profiles, routes of administration, and genetic
variability in opioid responses.
The transdermal route, which can be used with fentanyl or
buprenorphine, can be useful in patients with swallowing
difficulties. Oxycodone or hydromorphone may be given if
morphine causes hallucinations, excessive drowsiness, or
disturbed sleep.
Any opioid can accumulate in patients with renal
dysfunction. Care should always be taken in such patients, and
opioid doses should generally be lower than normal, with
increased intervals between doses or drugs administered as
required. Opioids such as fentanyl, alfentanil, hydromorphone,
and buprenorphine are usually acceptable in patients with renal
dysfunction but all require careful monitoring.
Tolerance, addiction, and physical
dependence
Tolerance to opioids is rarely seen in cancer patients.
Requirements for increasing doses of morphine can usually be
explained by progressive disease rather than tolerance.
Psychological dependence or addiction is not a problem,
except in some patients with pre-existing addiction. If
alternative methods of pain control are used (such as nerve
blocks) the dose of the analgesic can usually be reduced, even to
nothing, without adverse psychological effects. Physical
dependence can occur, and this physiological response can
manifest itself as a flu-like illness in some patients if an opioid is
discontinued suddenly.
Opioid toxicity
The dose of opioid that can be tolerated varies widely both
between and within individuals. Although toxicity can be
frightening and life threatening, it is usually reversible if it is
diagnosed early.
Opioid toxicity may present as subtle agitation, seeing
shadows at the periphery of the visual field, vivid dreams, visual
and auditory hallucinations, confusion, and myoclonic jerks.
Agitated confusion may be misinterpreted as uncontrolled pain
and further opioids given. A vicious cycle follows in which the
patient is given sedation and may become dehydrated, resulting
in the accumulation of opioid metabolites and further toxicity.
Management includes reducing the dose of opioid, ensuring
adequate hydration, and treating the agitation with haloperidol
(1.5-3 mg orally or subcutaneously, repeated hourly as needed).
If toxicity is severe and opioid analgesia is still needed, switching
the opioid usually leads to a faster recovery. If a different opioid
is required, a lower dose that the equianalgesic dose should
usually be prescribed. Before the more sophisticated use of
opioids, toxicity was often mislabelled as terminal agitation.
Rationale for alternative opioids
x Basic pharmacology of the drug and particular properties relating
to renal, hepatic, and cognitive impairment
x Progress in basic science, which has illuminated the genetic
differences between individuals in response to opioids
Common adverse effects of opioids
x Sedation—Some sedation is common at the start of treatment, but in
most patients it resolves within a few days
x Nausea and vomiting—Nausea is common in patients taking oral
morphine, vomiting rather less so. These are initial side effects and
usually resolve over a few days, but they can easily be
controlled—metoclopramide (10 mg every eight hours) or
haloperidol (1.5 mg at night or twice daily) is effective for most
patients
x Constipation develops in almost all patients and should be treated
prophylactically with laxatives
x Dry mouth is often the most troublesome adverse effect for patients.
Patients should be advised on simple measures to combat this, such
as frequent sips of iced drinks, saliva replacements, or saliva
stimulants
Factors that affect the ability to tolerate opioids
x The degree of responsiveness of the pain to opioid analgesia
x Previous exposure to opioids
x Rate of titration of the dose
x Concomitant medication
x Concomitant disease
x Genetic factors
x Biochemical factors such as renal function
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